product revenue · expensive to verify
AI-powered imaging and mapping in electrophysiology (CARTOSOUND SONATA)
Not sized
No sales, price or unit count is given for CARTOSOUND SONATA, and the AI capability is bundled into it, beside ultrasound imaging and mapping hardware and software, so nothing separates the AI part. The product’s sales sit inside electrophysiology sales, the ceiling of , whose growth management credits to other causes. Any ballpark would need two judgment shares in a row (the product’s share of electrophysiology, then AI’s share of the product); under the rule for AI named beside another cause, the channel is described and unsized and gets no ballpark built on a judgment AI share.
described, no sizedisclosure: described· motive: exploratory· before LLMs: relabelled
One sentence of the CEO’s prepared remarks is the only AI passage in any Q2 source: the debut of CARTOSOUND SONATA bringing AI-powered imaging and mapping capabilities to electrophysiology. The CFO names the product again among second-half catalysts, and the release lists its debut as CARTO-powered innovation (claim c8), neither saying AI: those two passages count in the scan only because the product name is in the company’s vocabulary, so two of the three Q2 passages are product-name passages and one says AI. Electrophysiology sales rose by to , or of company sales, and neither the call nor the 10-Q ties any of the movement to the product or to AI. The channel is read described, relabelled at registration, and left unsized.
Evidence: 5 quotes, 5 figures, 4 confounds, 3 from before coverage
Sales of electrophysiology mapping and imaging equipment that the CEO credits with AI-powered imaging and mapping capabilities: CARTOSOUND SONATA, which debuted in Q2 2026 and which the CFO expects to keep gaining adoption in the U.S. The payers are hospitals and electrophysiology labs. No source gives a price, a unit count or sales for the product, and the 10-Q does not name it among the new products behind electrophysiology growth; its sales sit inside electrophysiology sales, which also hold ablation catheters (VARIPULSE, TRUPULSE, NUVISION, CRYSTAL), so electrophysiology sales are the ceiling on any AI part. The AI capability is one attribute of a product that also carries ultrasound and mapping hardware and software, so the AI part is named beside other causes and nothing separates it. Surgical robotics (OTTAVA, MONARCH, VELYS) and the Polyphonic digital ecosystem are not in this channel: the sources describe them as robotic, automated, digital and data-driven and never as AI.
Why this motive
The CEO names AI-powered imaging and mapping as a capability of a product that debuted in the quarter (claim c1) and the CFO expects continued adoption (claim c2), with no price, attach rate, unit count or sales: the offensive tell needs a separately priced AI product or a measured movement attributed to AI, and neither is given. AI named as a cause with no measure and no line moving because of it is the exploratory tell.
Before LLMs: relabelled
At the anchor Biosense Webster already sold high density mapping catheters and ultrasound catheters (claim jnj-anchor-c3) within the electrophysiology products of the Cardiovascular portfolio (claim jnj-anchor-c2); electrophysiology sales were in FY2024. The FY2024 10-K’s risk factor that the company used machine learning and other forms of AI across its business (claim jnj-anchor-c1) is general and names no product, so the tag does not rest on it. Management gives no measure of demand attributable to the AI-powered capabilities, so the tie-break reads the channel as existing mapping and imaging sales described with AI named.
“The Company leverages the use of data science, machine learning and other forms of AI and emerging technologies across varying parts of its business and operations, and the introduction and incorporation of AI may result in unintended consequences or other new or expanded risks and liabilities.”
“The Cardiovascular (previously referred to as Interventional solutions) portfolio includes electrophysiology products to treat heart rhythm disorders, the heart recovery portfolio (Abiomed) which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock, circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD), and neurovascular care that treats hemorrhagic and ischemic stroke.”
“The complaint alleges that certain of BWI's business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters.”
Figures
- Electrophysiology sales, the ceiling on the AI part · 2026-CQ2
- Electrophysiology sales, prior-year quarter · 2025-CQ2
- Change in electrophysiology sales on the prior-year quarter · 2026-CQ2
- Electrophysiology operational sales growth · 2026-CQ2
- Electrophysiology sales as a share of sales to customers · 2026-CQ2
What else could explain it
- line composition: Electrophysiology sales of hold ablation catheters, mapping and imaging systems and other products; the 10-Q credits growth to new ablation catheters (VARIPULSE, TRUPULSE, NUVISION and CRYSTAL) and does not name CARTOSOUND SONATA (claim c4).
- other: Electrophysiology operational growth of is credited to procedure growth, commercial execution and new product performance, offset by competitive pulsed field ablation pressure (claim c3) and a China inventory effect estimated at ; AI is not among the causes management gives for the line.
- bundling: The AI-powered capability comes inside a product that also carries ultrasound and mapping hardware and software, with no separate price, so even the product’s own sales would not separate the AI part.
- relabel: Mapping catheters and ultrasound catheters were already sold at the anchor (claim jnj-anchor-c3), within the electrophysiology products of the Cardiovascular portfolio (claim jnj-anchor-c2), and the release presents the product as CARTO-powered (claim c8); management gives no measure of demand attributable to the AI-powered capabilities.
Quotes
“In Q2, our position was further strengthened with the debut of CARTOSOUND SONATA, bringing new AI-powered imaging and mapping capabilities to electrophysiology.”
“In electrophysiology, we expect continued adoption of CARTOSOUND SONATA cardio mapping in the U.S. and VARIPULSE Pro in EMEA, with anticipated approval of VARIPULSE Pro in the U.S. later this year.”
“Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026”
“In electrophysiology, growth of 3.1% was driven by procedure growth, commercial execution, and new product performance, partially offset by competitive PFA pressures.”
“Electrophysiology sales growth was driven by procedure growth, commercial execution and new product performance (VARIPULSE, TRUPULSE, NUVISION and CRYSTAL) partially offset by competitive pressures in Pulsed Field Ablation catheters and China inventory dynamics.”